Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized TherapyVignesh Narasimhan, Susan L. Woods, Josephine A. Wright et al.|Clinical Cancer Research|2020Cited by 185
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testingHeidi J. Gray, Carla Grandori, Hallie A. Swan et al.|npj Precision Oncology|2023Cited by 26
Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinomaMarwah Al-Aloosi, Carla Grandori, Amanda M. Prechtl et al.|Frontiers in Oncology|2024Cited by 8
Predictive value of a CLIA-approved organoid based drug sensitivity test.Astrid Margossian, Carla Grandori, Annie Richardson et al.|Journal of Clinical Oncology|2020Cited by 6
Abstract 1619: Personalized medicine: A CLIA-certified high-throughput drug screening platform for ovarian cancerHallie A. Swan, Carla Grandori, Rachele Rosati et al.|Cancer Research|2018Cited by 5